J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)
Jonathan A. Ledermann,G. J. S. Rustin,A. Hackshaw,Stan B. Kaye,Gordon C Jayson,Hani Gabra,LE James,S. Bell,Graham Temple +8 more
TL;DR: It is suggested that maintenance BIBF 1120 could delay disease progression in OC pts who had previously responded to chemotherapy, and a large phase III trial is needed to confirm the efficacy of this drug.
Journal ArticleDOI
Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
David J. Kerr,Jonathan A. Ledermann,Colin S. McArdle,John A. C. Buckels,John P. Neoptolemos,Matthew T. Seymour,J Doughty,J. Budden,I Taylor +8 more
TL;DR: A regimen that combines 5-FU and FA has been identified for regional chemotherapy in patients with hepatic metastases from colorectal cancer and implies that this chemotherapy has the best of both worlds, ie, a regional advantage in delivering high drug concentrations to the target organ with adequate systemic cover for extrahepatic micrometastases.
Journal ArticleDOI
Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial
Rob Glynne-Jones,Latha Kadalayil,Helen Meadows,David Cunningham,Leslie Samuel,J I Geh,Charles Lowdell,Roger D James,Sandy Beare,Rubina Begum,Jonathan A. Ledermann,David Sebag-Montefiore +11 more
TL;DR: The majority (52%) of pre-treatment colostomies were never reversed and neither CRT with 5FU/CisP nor maintenance chemotherapy impacted on CFS, and similar associations were found between PFS and tumour/treatment-related factors.
Journal ArticleDOI
A Multicentre Retrospective Cohort Study of Ovarian Germ Cell Tumours: Evidence for Chemotherapy De-Escalation and Alignment of Paediatric and Adult Practice
C. Newton,K. Murali,Amar Ahmad,Helen Hockings,Helen Hockings,R. Graham,V. Liberale,S.-J. Sarker,S.-J. Sarker,Jonathan A. Ledermann,Daniel M. Berney,Daniel M. Berney,Jonathan Shamash,Susana Banerjee,Sara Stoneham,Michelle Lockley,Michelle Lockley,Michelle Lockley +17 more
TL;DR: Findings that IT was chemotherapy resistant and pathological grade uninformative strongly endorse exclusive surgical management of ovarian ITs at all ages and support the extension of reduced-toxicity, paediatric regimens to adults.
Journal ArticleDOI
European Network of Gynaecological Oncological Trial Groups' requirements for trials between academic groups and pharmaceutical companies
Ignace Vergote,Eric Pujade-Lauraine,Sandro Pignata,Gunnar B. Kristensen,Jonathan A. Ledermann,Antonio Casado,Jalid Sehouli,Mansoor Raza Mirza,Roldano Fossati,Christian Marth,Carine Creutzberg,Jose Maria Del Campo,Nadeem Siddiqui,Paula Calvert,Aris Bamias,Gökhan Tulunay,Ate G.J. van der Zee,Andreas du Bois +17 more
TL;DR: The aim of this research was to establish a database of clinical practice in women’s gynaecological oncological trial groups and establish a baseline for the use of prognosis-based adjuvant chemotherapy for these patients.